CSBio CSBio

X
[{"orgOrder":0,"company":"RedHill Biopharma","sponsor":"State of Pennsylvania","pharmaFlowCategory":"D","amount":"$0.3 million","upfrontCash":"Undisclosed","newsHeadline":"RedHill Biopharma's Opaganib Awarded COVID-19 Grant by State of Pennsylvania","therapeuticArea":"Pulmonary\/Respiratory Diseases","highestDevelopmentStatus":"Phase II\/ Phase III","country":"ISRAEL","productType":"Small molecule","productStatus":"New Molecular Entity","date":"September 2020","url1":"","url2":"","graph1":"Small molecule","graph2":"RedHill Biopharma"}]

Find Clinical Drug Development Pipelines & Deals | PipelineProspector

Loading...
Filters Filter
×
FILTER:
filter News Type
    filter Company
      filter Product Type
        filter Deal Size
          filter Upfront Payment

            Active Filter(s):

            Product Type

            Companies

            Details:

            A global Phase 2/3 study in up to 270 patients hospitalized with severe COVID-19 pneumonia, and a U.S. Phase 2 study in up to 40 patients, are ongoing with opaganib, a novel sphingosine kinase-2 selective inhibitor with dual anti-inflammatory and anti-viral properties.

            Lead Product(s): Opaganib

            Therapeutic Area: Pulmonary/Respiratory Diseases Product Name: Yeliva

            Highest Development Status: Phase II/ Phase III Product Type: Small molecule

            Partner/Sponsor/Collaborator: State of Pennsylvania

            Deal Size: $0.3 million Upfront Cash: Undisclosed

            Deal Type: Funding September 03, 2020

            ASK
            US
            PHARMACOMPASS
            Upload
            your Pipeline Activity
            Post Enquiry
            POST ENQUIRY